<DOC>
	<DOCNO>NCT02063997</DOCNO>
	<brief_summary>The purpose study determine whether arhalofenate effective preventing flare reduce serum uric acid gout patient .</brief_summary>
	<brief_title>Evaluate Efficacy Safety Arhalofenate Preventing Flares Reducing Serum Uric Acid Gout Patients</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Colchicine</mesh_term>
	<mesh_term>Uric Acid</mesh_term>
	<criteria>Male female patient 18 75 year age , inclusive Known gout diagnosis ( per criterion American Rheumatism Association classification acute arthritis primary gout , see Appendix 3 ) At least three patientreported document flare 12 month prior screen ( first flare may result gout diagnosis ; recent flare must resolve , patient back usual comfort level least seven day prior screen ) Have use ULT since least two week prior screen Have use colchicine since least two week prior screen Usual level rest pain NOT experience flare three less 11point numerical rating scale ( NRS ) Have sUA ≥ 7.5 mg/dL ≤ 12 mg/dL screen All female patient must surgically sterile postmenopausal ( least 45 year age history menses least two year ) ; partner undergone vasectomy must agree use two medically accept method contraception include barrier method ( see Appendix 4 ) entire duration study participation unless report complete sexual abstinence . Female patient must pregnant lactating Estimated creatinine clearance ( eCrCl ) ≥ 60 ml/min/1.73m2 calculate CockcroftGault method screen Liver function test ≤ 3X ULN AST , ALT total bilirubin ; ≤ 3X ULN ALP GGT ; ≤ 3X ULN CK screen All clinical laboratory parameter must within normal limit consider clinically significant Electrocardiogram ( ECG ) must normal , abnormal , consider clinically significant screen Systolic blood pressure ≤ 160 mm Hg diastolic blood pressure ≤ 90 mm Hg screening ; know hypertensive patient stable ( blood pressure [ BP ] read ) medication may include Patients use agent know influence sUA level ( see Appendix 7 ) must stable dose regimen least two week prior screen must willing continue dos regimens study participation Expected able tolerate short course either oral NSAIDs and/or oral steroid may need treat flare Must able swallow tablets/capsules Following training , must willing able understand complete electronic diary Receiving treatment allopurinol , colchicine , probenecid , benzbromarone , febuxostat within two week pegloticase within six month prior screen Known suspect secondary hyperuricemia ( e.g . due myeloproliferative disorder organ transplant ) Diagnosis xanthinuria Fractional excretion urate &gt; 10 % screen History document suspected kidney stone Known infection human immunodeficiency virus ( HIV ) history viral hepatitis type B C A diagnosis illicit drug alcohol dependence abuse within one year screen History upper gastrointestinal ( GI ) bleeding , document peptic ulcer disease ( unless know H. pylori infection treat successfully without recurrence ) , within three year screen History stroke , transient ischemic attack ( TIA ) , acute myocardial infarction ( MI ) , congestive heart failure ( NYHA Class IIIV ) , angina pectoris , coronary intervention procedure ( include limit angioplasty , stent placement , coronary revascularization ) , low extremity bypass procedure , systemic intracoronary fibrinolytic therapy within five year screen History cancer within five year screen , follow exception : adequately treat nonmelanomatous skin cancer , nonmetastatic prostate cancer situ cervical cancer Patients history bladder cancer , active bladder cancer hematuria Body mass index ( BMI ) &gt; 42 kg/m2 screen Current expect requirement anticoagulant therapy ( except aspirin ≤ 325 mg/day , clopidogrel [ Plavix ] ≤ 75 mg/day , prasugrel [ Effient ] ≤ 10 mg/day ) Use follow within eight week prior screen : potent CYP3A4 inhibitor , cytotoxic agent ( include azathioprine , mercaptopurine , cyclosporine , cyclophosphamide , etc . ) , ranolazine , digoxin , theophylline , sulphonylureas , thiazolidinediones ( e.g. , rosiglitazone pioglitazone ) , atypical antipsychotic agent , ampicillin , amoxicillin , loop diuretic phenytoin Chronic treatment NSAIDs ( except need [ prn ] use treat acute event ) ; per protocol short course oral NSAIDs may use treat flare study Current expect chronic treatment systemic corticosteroid ( topical , ophthalmic , intraarticular inhale corticosteroid dose &lt; 1600 μg/day permit ) ; per protocol short course oral corticosteroid may use treat flare occur study History intraarticular steroid injection treat flare within four week screen Known hypersensitivity intolerance allopurinol colchicine Treatment investigational therapy within 30 day within five half life , whichever longer , prior screening Patients receive arhalofenate previous trial Any condition ( ) would compromise safety patient , prevent compliance study protocol include ability use electronic diary , compromise quality clinical study , judge Investigator and/or Medical Monitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>